Clenoliximab

Clenoliximab (INN[1]) is a monoclonal antibody against CD4. It acts as an immunomodulator and has been investigated for the treatment of rheumatoid arthritis.[2] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[1]

Clenoliximab
Monoclonal antibody
TypeWhole antibody
SourceChimeric (primate/human)
TargetCD4
Clinical data
ATC code
  • none
Identifiers
ChemSpider
  • none
 NY (what is this?)  (verify)

References
  1. World Health Organization (1997). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 77" (PDF). WHO Drug Information. 11 (2): 89.
  2. Hepburn TW, Totoritis MC, Davis CB (January 2003). "Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis". Rheumatology. 42 (1): 54–61. doi:10.1093/rheumatology/keg030. PMID 12509613.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.